SPRi (Surface Plasmon Resonance Imaging) biosensors are used for detection in real time with advantage of processing large number parallel measurements. Our goal is fast detection of low concentrations of ovalbumin and similar proteins. A low concentration testing of proteins in urea or blood serum is needed for clinical tests. The current SPRi method is not capable of measuring ovalbumin concentrations lower than 1 mg/l directly. This article shows measurements of biochemical substance concentrations and a possibility of identification of very low concentrations on several experiments. Strengthening of the signal was achieved by coupling of a secondary biotinylized antibody (anti-ovalbumin), to which streptavidin is further attached. and Bionsenzory SPRi (Surface Plasmon Resonance Imaging) jsou používány pro detekci v reálném čase s výhodou zpracování velkého počtu paralelních měření. Naším cílem je detekce nízkých koncentrací ovalbuminu a podobných proteinů. Testování nízké koncentrace proteinů v moči a krevním séru jsou nutné pro klinické zkoušky. Současná metoda SPRi nedokáže přímo měřit koncentrace ovalbuminu nižší než 1 mg/l. V tomto příspěvku je na několika experimentech předvedeno měření koncentrací biochemické substance a možnost určení velmi nízkých koncentrací. Zesílení signálu bylo dosaženo přidáním biotinu a streptavidinu.
Application of Surface Plasmon Resonance (SPR) is one from the most developed optical detection techniques in the frame of biosensors. Surface Plasmon Resonance imaging (SPRi) can monitor biomolecular interactions and detect materials without previous marking of biochemical. We can on line monitor the biochip surface during the biomolecules interactions. It is possible to measure simultaneously several tens of various interactions. The motivation consists in the determination of ovalbumine level in the patient’s urine. and Aplikace rezonanční excitace povrchových plasmonů (SPR, Surface Plasmon Resonance) patří mezi jednu z nejrozvinutějších optických detekčních technik v oblasti biosenzorů. SPRi (SPRi, Surface Plasmon Resonance imaging) umožňuje monitorovat interakce biomolekul a detekovat látky bez nutnosti předchozího značení jedné z biochemikálií. V reálném čase lze sledovat přímo zobrazení povrchu biočipu při interakcích biomolekul. Lze paralelně měřit několik desítek různých interakcí. Motivací je možnost specifikovat hladinu ovalbuminu v moči pacientů.
Early diagnosis of ongoing malignant disease is crucial to improve survival rate and life quality of the patients and requires sensitive detection of specific biomarkers e.g. prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), etc. In spite of current technological advances, malignant diseases are still identified in rather late stages, which have detrimental effect on the prognosis and treatment of the disease. Here, we present a biosensor able to detect fetuin-A, a potential multibiomarker. The biosensing platform is based on polymer brush combining antifouling monomer units of N -(2-hydroxypropyl)methacrylamide (HPMA) and carboxybetaine methacrylamide (CBMAA), statistically copolymerized by surfaceinitiated atom transfer radical polymerization. The copolymer poly(HPMA-co-CBMAA) exhibits excellent non-fouling properties in the most relevant biological media (i.e. blood plasma) as well as antithrombogenic surface properties by preventing the adhesion of blood components (i.e. leukocytes; platelets; and erythrocytes). Moreover, the polymer brush can be easily functionalized with biorecognition elements maintaining high resistance to blood fouling and the binding capacity can be regulated by tuning the ratio between CBMAA and HPMA units. The superior antifouling properties of the copolymer even after biofunctionalization were exploited to fabricate a new plasmonic biosensor for the analysis of fetuin-A in real clinical blood plasma samples. The assay used in this work can be explored as labelfree affinity biosensor for diagnostics of different biomarkers in real clinical plasma samples and to shift the early biomarker detection toward novel biosensor technologies allowing point of care analysis., Z. Riedelová, P. Májek, K. Pečánková, J. Kučerová, F. Surman, A. De Los Pereira, T. Riedel., and Obsahuje bibliografii